TCGA-UY-A8OD-01A-11R-A36F-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 112.7463863
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- COAGULATION+0.430
- MYOGENESIS+0.410
- ANGIOGENESIS+0.400
- KRAS_SIGNALING_DN+0.340
- KRAS_SIGNALING_UP+0.310
- ALLOGRAFT_REJECTION+0.300
- PANCREAS_BETA_CELLS+0.240
- UV_RESPONSE_DN+0.230
- HEDGEHOG_SIGNALING+0.210
Top 10 suppressed
- E2F_TARGETS-0.540
- MYC_TARGETS_V2-0.530
- MYC_TARGETS_V1-0.510
- UNFOLDED_PROTEIN_RESPONSE-0.510
- PROTEIN_SECRETION-0.480
- INTERFERON_ALPHA_RESPONSE-0.470
- G2M_CHECKPOINT-0.460
- MITOTIC_SPINDLE-0.420
- PI3K_AKT_MTOR_SIGNALING-0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-ZF-A9R9-01A-11R-A38B-07 | — | — | 0.948 |
| 2 | DRR168582 | — | — | 0.919 |
| 3 | SRR12202435 | — | — | 0.914 |
| 4 | aMVAC.P_004_TURBT_S222 | — | — | 0.909 |
| 5 | SRR1457503 | GTEX | — | 0.908 |
| 6 | SRR1353221 | GTEX | — | 0.906 |
| 7 | 15-109pB4_FFPE | — | — | 0.901 |
| 8 | TCGA-49-4512-01A-21R-1858-07 | — | cohortA1 | 0.896 |
| 9 | SRR612563 | GTEX | — | 0.895 |
| 10 | SRR1317853 | GTEX | — | 0.891 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| MYOGENESIS | 0.410 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.340 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| COMPLEMENT | 0.160 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.120 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |
| HYPOXIA | 0.040 | Idelalisib | — uncovered |